Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 69.13% |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 2.86% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 19.56% |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 13.19% |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 56.51% |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 25.91% |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | -1.67% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | -4.65% |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | -1.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.91% |
| Mar 31, 2026 | 37.30% |
| Dec 31, 2025 | 206.01% |
| Sep 30, 2025 | -2.55% |
| Jun 30, 2025 | 88.98% |
| Mar 31, 2025 | -51.02% |
| Dec 31, 2024 | -10.07% |
| Sep 30, 2024 | 18.86% |
| Jun 30, 2024 | -12.80% |
| Mar 31, 2024 | 281.79% |
| Dec 31, 2023 | -4.29% |
| Sep 30, 2023 | 38.41% |
| Jun 30, 2023 | -1.90% |
| Mar 31, 2023 | -61.58% |
| Dec 31, 2022 | -21.31% |
| Sep 30, 2022 | -31.79% |
| Jun 30, 2022 | -55.63% |
| Mar 31, 2022 | -23.37% |
| Dec 31, 2021 | 80.77% |
| Sep 30, 2021 | -26.85% |